Coherus BioSciences Stock Forecast, Price & News

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Coherus BioSciences in the last twelve months. There are currently 2 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" Coherus BioSciences stock.
View analyst ratings for Coherus BioSciences or view top-rated stocks.

5 equities research analysts have issued 12 month price targets for Coherus BioSciences' stock. Their CHRS stock forecasts range from $7.00 to $30.00. On average, they anticipate Coherus BioSciences' share price to reach $19.00 in the next twelve months. This suggests a possible upside of 142.7% from the stock's current price.
View analysts' price targets for Coherus BioSciences or view top-rated stocks among Wall Street analysts.

Coherus BioSciences' stock was trading at $15.96 on January 1st, 2022. Since then, CHRS stock has decreased by 50.9% and is now trading at $7.83.
View the best growth stocks for 2022 here.

Coherus BioSciences is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for Coherus BioSciences.

Coherus BioSciences, Inc. (NASDAQ:CHRS) issued its earnings results on Thursday, May, 5th. The biotechnology company reported ($1.24) EPS for the quarter, missing the consensus estimate of ($0.80) by $0.44. The biotechnology company had revenue of $60.12 million for the quarter, compared to the consensus estimate of $68.07 million. Coherus BioSciences had a negative trailing twelve-month return on equity of 211.68% and a negative net margin of 69.24%.
View Coherus BioSciences' earnings history.

21 employees have rated Coherus BioSciences CEO Dennis M. Lanfear on Glassdoor.com. Dennis M. Lanfear has an approval rating of 95% among Coherus BioSciences' employees. This puts Dennis M. Lanfear in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Coherus BioSciences include Twist Bioscience (TWST), BioCryst Pharmaceuticals (BCRX), Relay Therapeutics (RLAY), Iovance Biotherapeutics (IOVA), Krystal Biotech (KRYS), Allogene Therapeutics (ALLO), Immunocore (IMCR), ImmunityBio (IBRX), Revolution Medicines (RVMD), Recursion Pharmaceuticals (RXRX), Exscientia (EXAI), SpringWorks Therapeutics (SWTX), Vaxcyte (PCVX), Sana Biotechnology (SANA) and Vericel (VCEL).
View all of CHRS's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Coherus BioSciences investors own include Halozyme Therapeutics (HALO), Chembio Diagnostics (CEMI), Exelixis (EXEL), Heron Therapeutics (HRTX), TG Therapeutics (TGTX), Intelsat (I), Idera Pharmaceuticals (IDRA), Immunomedics (IMMU), Sangamo Therapeutics (SGMO) and Viking Therapeutics (VKTX).

Coherus BioSciences trades on the NASDAQ under the ticker symbol "CHRS."

Shares of CHRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CHRS stock can currently be purchased for approximately $7.83.

Coherus BioSciences (NASDAQ:CHRS) has a market capitalization of $606.22 million and generates $326.55 million in revenue each year. The biotechnology company earns $-287.10 million in net income (profit) each year or ($2.730010) on an earnings per share basis.

Coherus BioSciences employs 332 workers across the globe.

Coherus BioSciences was founded in 2010.

Coherus BioSciences' mailing address is 333 TWIN DOLPHIN DRIVE SUITE 600, REDWOOD CITY CA, 94065. The official website for Coherus BioSciences is www.coherus.com. The biotechnology company can be reached via phone at (650) 649-3530 or via email at darrington@coherus.com.